Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers
August 1, 2020
Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers.